Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Prime Medicine (PRME) Interest & Investment Income (2023 - 2025)

Prime Medicine (PRME) has disclosed Interest & Investment Income for 3 consecutive years, with $1.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Interest & Investment Income fell 29.58% year-over-year to $1.1 million, compared with a TTM value of $4.1 million through Dec 2025, up 17.8%, and an annual FY2025 reading of $4.1 million, up 17.8% over the prior year.
  • Interest & Investment Income was $1.1 million for Q4 2025 at Prime Medicine, down from $1.1 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $1.5 million in Q4 2024 and bottomed at $410000.0 in Q3 2023.
  • Average Interest & Investment Income over 3 years is $857200.0, with a median of $720000.0 recorded in 2024.
  • The sharpest move saw Interest & Investment Income soared 213.24% in 2024, then fell 29.58% in 2025.
  • Year by year, Interest & Investment Income stood at $491000.0 in 2023, then skyrocketed by 213.24% to $1.5 million in 2024, then dropped by 29.58% to $1.1 million in 2025.
  • Business Quant data shows Interest & Investment Income for PRME at $1.1 million in Q4 2025, $1.1 million in Q3 2025, and $743000.0 in Q2 2025.